Tezspire(tezepelumab)
Tezspire (tezepelumab) is an antibody pharmaceutical. Tezepelumab was first approved as Tezspire on 2021-12-17. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Tezspire
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tezepelumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Tezspire | tezepelumab-ekko | AstraZeneca | N-761224 RX | 2021-12-17 | 3 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tezspire | Biologic Licensing Application | 2021-12-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| asthma | EFO_0000270 | D001249 | J45 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 4 | 4 | 10 | 1 | — | 19 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nasal polyps | D009298 | HP_0100582 | J33 | — | — | 1 | — | — | 1 |
| Airway remodeling | D056151 | — | — | 1 | — | — | 1 | ||
| Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 2 | — | — | — | 3 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 2 | — | — | — | 2 |
| Immune system diseases | D007154 | D89.9 | — | 2 | — | — | — | 2 | |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | 2 | — | — | — | 2 |
| Chronic urticaria | D000080223 | L50.8 | — | 1 | — | — | — | 1 | |
| Respiratory tract diseases | D012140 | — | 1 | — | — | — | 1 | ||
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | — | — | — | 1 |
| Bronchial diseases | D001982 | — | 1 | — | — | — | 1 | ||
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | — | — | — | 1 | |
| Immediate hypersensitivity | D006969 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | — | 4 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TEZEPELUMAB |
| INN | tezepelumab |
| Description | Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma. Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >5J13:B|anti-TSLP Fab-fragment, light chain
MGILPSPGMPALLSLVSLLSVLLMGCVAETGSYVLTQPPSVSVAPGQTARITCGGNNLGSKSVHWYQQKPGQAPVLVVYD
DSDRPSWIPERFSGSNSGNTATLTISRGEAGDEADYYCQVWDSSSDHVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQA
NKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVA
PTECS
>5J13:C|anti-TSLP Fab-fragment, heavy chain
MGILPSPGMPALLSLVSLLSVLLMGCVAETGQMQLVESGGGVVQPGRSLRLSCAASGFTFRTYGMHWVRQAPGKGLEWVA
VIWYDGSNKHYADSVKGRFTITRDNSKNTLNLQMNSLRAEDTAVYYCARAPQWELVHEAFDIWGQGTMVTVSSASTKGPS
VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDH
KPSNTKVDKTVERKGTKHHHHHH |
Identifiers
| PDB | 5J13 |
| CAS-ID | 1572943-04-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3707229 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15090 |
| UNII ID | RJ1IW3B4QX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Tezspire - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 597 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more